 | |
| Company type | Subsidiary |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 2010; 14 years ago (2010), in Waltham, Massachusetts |
| Headquarters |
,
United States
 |
| Products | Varubi |
Number of employees | 286 (2016) |
| Parent | GSK (2019–present) |
| Website | tesarobio |
Tesaro Inc. is a pharmaceutical company based in Waltham, Massachusetts. They focus on drug development for cancer.
Tesaro was founded in 2010.[1] The company's first commercial product, Varubi, was approved by the FDA in October 2015.[2] As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD.[3] The company's product Niraparib was granted priority review and was given a target action date of June 2017 by the FDA.[4] In March 2017, Tesaro won approval for its drug Zejula to treat ovarian cancer.[5] On May 31, 2017, it was reported that Tesaro Inc. was exploring a sale.[5] On December 3, 2018, GSK announced it would acquire the company for $5.1 billion,[6] and the deal was completed on January 22, 2019.[7]
{{citation}}: CS1 maint: bot: original URL status unknown (link)
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Subsidiaries |
| ||||||||
| Predecessors, acquisitions |
| ||||||||
| Products |
| ||||||||
| People |
| ||||||||
| Litigation |
| ||||||||
| Other |
| ||||||||
| |||||||||
